A $250M target fund combining healthcare operating earnings, clinical-translation infrastructure and milestone-driven therapeutic upside.
Available to accredited investors only. Access to the deck and data room is granted after an application and executed non-disclosure agreement.
Breakthrough biology frequently stalls for want of manufacturing, patient access, evidence and operating infrastructure. Aether invests across the continuum that turns science into real-world impact.
A continuum from science to a healthier, longer tomorrow. Value depends on execution, evidence and market conditions.
A single fund commitment provides blended exposure to selective innovation, enabling services, healthcare AI and cash-flow acquisitions.
Milestone-driven equity in platform biology. Value depends on scientific, regulatory, CMC and controlled-evidence milestones.
Manufacturing and biofabrication, access and evidence, healthcare AI, and operating acquisitions — earnings and platform value that can support portfolio execution.
Innovation capital is staged to defined, verifiable evidence gates — fund, prove, and advance or stop at each milestone.
Acquisition strategy is underwritten to operating earnings and transaction discipline, not multiple expansion alone.
A general-partner group combining biotech, clinical, operating and healthcare transaction experience, with scientific advisers.
Important information. This website is confidential discussion material intended solely for accredited investors and is not an offer to sell or a solicitation of an offer to buy any security. Any offering will be made only through definitive offering documents and in accordance with applicable securities exemptions.
Interests are restricted and illiquid. The Fund may not reach its target size, complete transactions, make distributions or achieve any modeled outcome, and investors may lose all invested capital. Statements about portfolio companies, targets, valuations, timelines and strategy are forward-looking and may prove wrong; they are not performance, promises or guarantees. Recipients should conduct independent legal, tax, accounting, scientific and investment diligence. Nothing here replaces professional advice or formal offering documentation.
